My BIO
Joseph S. Dillon, PH.D., MBA
Chairman and Chief Executive Officer
Joseph S. Dillon, Ph.D., MBA, joined EpiTET as Chairman and Chief Executive Officer in 2025. Dr. Dillon is also President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 30 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology/deal valuations.
Dr. Dillon has valued over 450 deals and has been a lead on nearly 50 strategic transactions with a value exceeding $20B. He has consulted dozens of companies and held senior positions, including CEO, CBO, and CFO at select clients. Prior to this, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group/KantarHealth.
Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center (sold to AAI), a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company (lead IPO, then sold to US Bancorp); CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector.
He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Metaphysical Sciences/Theoretical Physics, an M.B.A. in International Finance, with emphasis in investment banking, and a bachelor’s degree in finance.
Our Team
George D. Maynard, Ph.D.
Consultant, Advisor
⦁ 30+ years experience in pharmaceutical R& D
⦁ Served as President and Chief Scientific Officer of ReNetX Bio, VP Early Development at Neurogen, Project Team Leader at Hoechst Marion Roussel
⦁ Medicinal chemist with extensive experience in drug discovery, non-clinical and clinical development
⦁ Advanced multiple programs from early stage through clinical testing
Yingqun Huang MD, PHD
Scientific Founder
Professor, OB/GYN
Yale School of Medicine
Dr. Yingqun Huang received her undergraduate and medical degrees and her Ph.D. in Biomedical Sciences from the University of Connecticut Health Center in 1997. She carried out her postdoctoral studies with Dr. Gordon Carmichael at the University of Connecticut Health Center (1997-1999) and then with Dr. Joan Steitz at Yale University School of Medicine (1999-2003) prior to becoming an Assistant Professor in 2003 in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. She was promoted to Associate Professor in 2010 and then Full Professor in 2020.
Her lab research centers on the mechanistic understanding of metabolic disorders including obesity, diabetes and infertility, in addition to reproductive tract tumors. Using cell and mouse models and an interdisciplinary approach her group generates new insights into disease pathogenesis with the ultimate goal of leveraging the knowledge to improve human health.’
Her current research projects include 1) TET3-mediated regulation of hepatic glucose production, NAFLD and liver fibrosis; 2) the role of TET3 in modulation of skeletal muscle insulin sensitivity; 3) the regulation of feeding, obesity, and other complex behaviors by TET3 through the hypothalamic AGRP neurons; and 4) development of therapeutic approaches (small molecule compounds and RNA therapeutics) to eating disorders, stress-related disorders, NAFLD, liver fibrosis, endometriosis, and ovarian cancer.
Anand Kothandan
Secretary and Chief Operating Officer
Seasoned operations leader with over 17+ years of experience orchestrating operational
excellence across complex organizations. Proven expertise in strategic transformation, cross-functional leadership, financial modeling and sustainable growth initiatives. Consistently delivered improvements in operational efficiency and cost reduction through innovative process
optimization. Passionate about leveraging data-driven strategies and innovation to optimize
resource allocation and strengthen stakeholder relationships for long-term, sustainable growth.